NTRK1 and metastatic neoplasm: Increasing requests for NTRK testing by treating physicians, often on limited specimens for advanced or metastatic disease in hopes of identifying an actionable alteration, prompted us to validate and use the pan-TRK diagnostic immunohistochemical assay Ventana pan-TRK (EPR17341) assay as a screening modality for actionable NTRK fusions in our laboratory.